Merck to acquire Curon Biopharmaceutical’s CN201 in strategic oncology expansion
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, has secured a pivotal acquisition by agreeing to purchase CN201, an investigational B-cell depletion therapy, from Curon Biopharmaceutical for $700 million in cash. This acquisition highlights Merck’s commitment to enhancing its oncology pipeline with cutting-edge therapies. Strategic Acquisition Enhances Merck’s […]